Quantum Simulation Technologies, Inc.
MA · Founded 2018 · CIK 0001787657 · Biotech · Private
Quantum mechanics-based computational chemistry software for drug discovery that replaces classical approximations with quantum mechanical calculations for ligand-binding predictions
quantum.bio →- Grants
- $4.2M
- 13 awards
- Sector median: 1
- Raised
- $7.3M
- 3 Form D · Apr 2021
- 66 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $750,000 | |
| Private capital raised | Form D · SEC | $750,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Scoring ligand/protein interactions using a novel high performance implementation of DFT quantum mechanics | $147,454 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Scoring ligand/protein interactions using a novel high performance implementation of DFT quantum mechanics | $147,454 | |
| Private capital raised | Form D · SEC | $5,830,794 | |
| Federal grant | Department of Energy · Phase I · Cloud-based Low-Scaling Quantum Chemistry Simulations for Materials | $250,000 | |
| Federal grant | National Science Foundation · Phase I · SBIR Phase I:Matrix product state-based fermionic quantum emulator | $256,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Next generation free energy perturbation (FEP) calculations--enabled by a novel integration of quantum mechanics (QM) with molecular dynamics allowing a large QM region and no sampling compromises | $148,932 | |
| Federal grant | Department of Health and Human Services · Phase I · Next generation free energy perturbation (FEP)calculations--enabled by a novel integration of quantum mechanics (QM) with molecular dynamics allowing a large QM region and no sampling compromises | $148,932 | |
| Federal grant | Department of Health and Human Services · Phase I · Absolute binding free energies for virtual screening: A novel implementation of quantum mechanics/molecular mechanics (QM/MM) for FEP that allows substantial sampling and a significant quantum region | $273,361 | |
| Federal grant | Department of Health and Human Services · Phase I · Absolute binding free energies for virtual screening: A novel implementation of quantum mechanics/molecular mechanics (QM/MM) for FEP that allows substantial sampling and a significant quantum region | $273,361 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Improved optimization of covalent ligands using a novel implementation of quantum mechanics suitable for large ligand/protein systems. | $148,629 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Improved optimization of covalent ligands using a novel implementation of quantum mechanics suitable for large ligand/protein systems. | $148,629 | |
| Federal grant | Department of Health and Human Services · Phase I · Binding free energy predictions for peptide drugs: A novel machine learning-based peptide simulation model for high-throughput computational lead optimization with quantum mechanical accuracy. | $272,369 | |
| Federal grant | Department of Health and Human Services · Phase II · Next generation free energy perturbation (FEP) calculations--enabled by a novel integration of quantum mechanics (QM) with molecular dynamics allowing a large QM region and no sampling compromises | $1,022,908 | |
| Federal grant | Department of Health and Human Services · Phase II · Next generation free energy perturbation (FEP) calculations--enabled by a novel integration of quantum mechanics (QM) with molecular dynamics allowing a large QM region and no sampling compromises | $994,097 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2519 | SIVEC BIOTECHNOLOGIES, INC. | — | $3.3M |
| 2520 | MOUNTAIN VALLEY MD INC. | — | $18M |
| 2521 | Botanix Pharmaceuticals Ltd. | — | $20M |
| 2522 | Quantum Simulation Technologies, Inc. | — | $7.3M |
| 2523 | NeXtGen Biologics, INC | — | $2.9M |
| 2524 | ASSAYQUANT TECHNOLOGIES, INC. | — | $9.6M |
| 2525 | Sonata Biosciences Inc | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Garnet ChanDirector · Executive Officer · Promoter
- Guanhua ChenDirector
- Chan GarnetDirector
- Toru ShiozakiDirector · Executive Officer · Promoter
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.